Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== Brigatinib ====== [[Brigatinib]] (AP26113) (by Ariad) (breakthrough status in U.S.) (also an EGFR inhibitor) Brigatinib, a next-generation [[ALK inhibitor]], shows promising activity in [[Anaplastic lymphoma kinase non small cell lung cancer]] that have previously received [[crizotinib]] with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9.2-12.9 months. Randomized Phase III trial, ALTA-1 L is investigating brigatinib in ALK inhibitor-naive patients ((Amanam I, Gupta R, Mambetsariev I, Salgia R. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Feb 16. doi: 10.2217/fon-2017-0545. [Epub ahead of print] PubMed PMID: 29451020. )). brigatinib.txt Last modified: 2024/06/07 03:00by 127.0.0.1